Neurocrine Biosciences, Inc. (NBIX)’s Chief Executive Officer Kevin Gorman Sold 3750 shares of the Company; 18 Analysts Are Bullish The Ultimate Software Group, Inc. (ULTI) Last Week

Among 26 analysts covering Ultimate Software (NASDAQ:ULTI), 18 have Buy rating, 1 Sell and 7 Hold. Therefore 69% are positive. Ultimate Software had 56 analyst reports since October 22, 2015 according to SRatingsIntel. As per Wednesday, October 28, the company rating was maintained by Northland Capital. RBC Capital Markets maintained the shares of ULTI in report on Sunday, October 8 with “Buy” rating. As per Monday, October 16, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by Roth Capital given on Monday, July 31. The stock of The Ultimate Software Group, Inc. (NASDAQ:ULTI) earned “Outperform” rating by Wedbush on Monday, October 31. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, November 2. The stock of The Ultimate Software Group, Inc. (NASDAQ:ULTI) has “Buy” rating given on Wednesday, August 2 by Canaccord Genuity. The firm has “Buy” rating by Deutsche Bank given on Wednesday, October 28. As per Tuesday, September 20, the company rating was initiated by Pacific Crest. Piper Jaffray reinitiated the shares of ULTI in report on Wednesday, June 1 with “Overweight” rating. See The Ultimate Software Group, Inc. (NASDAQ:ULTI) latest ratings:

16/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $250.0 Maintain
10/01/2018 Broker: Guggenheim Rating: Buy New Target: $245.0 Maintain
08/01/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Old Target: $200 Upgrade
06/11/2017 Broker: Bank of America Rating: Underperform New Target: $187 Initiates Coverage On
02/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $225 New Target: $240 Maintain
02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $250.0 Maintain
02/11/2017 Broker: Wells Fargo Rating: Buy New Target: $240.0 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $220.0 Maintain
29/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $225.0 Maintain
16/10/2017 Broker: Needham Rating: Buy New Target: $250.0 Maintain

Neurocrine Biosciences Inc Chief Executive Officer Kevin Gorman on the 18-01-2018 unloaded a total of 3,750 shares of the California-based Neurocrine Biosciences Inc valued at $295,820 U.S. Dollars. This is at an average stock price per share of $78.9 U.S. Dollars. This specific sale was filled on 18-01-2018 and is accessible online on the Washington-based SEC’s website. Kevin Gorman holds roughly 0.38% of Neurocrine Biosciences Inc’s market capitalization or 336,357 shares.

The stock increased 3.53% or $2.68 during the last trading session, reaching $78.56. About 881,999 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since January 18, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Among 12 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci has $139.0 highest and $58.0 lowest target. $84.50’s average target is 7.56% above currents $78.56 stock price. Neurocrine Biosci had 41 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird on Monday, October 23 with “Buy”. The rating was maintained by Oppenheimer with “Buy” on Tuesday, December 12. Oppenheimer maintained the shares of NBIX in report on Wednesday, July 5 with “Buy” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, October 3 by BMO Capital Markets. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, November 2. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Wednesday, October 25 by Piper Jaffray. The company was maintained on Monday, September 25 by Cowen & Co. The rating was maintained by Oppenheimer with “Buy” on Monday, January 15. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Thursday, August 3 by BMO Capital Markets. H.C. Wainwright maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Friday, August 4 with “Buy” rating.

Since August 4, 2017, it had 0 insider buys, and 11 sales for $10.34 million activity. On Friday, August 4 the insider Bozigian Haig P. sold $1.13M. Lloyd-Smith Malcolm sold $1.40 million worth of stock or 18,084 shares. OBrien Christopher Flint sold $3.04M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, September 5. 5,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $275,000 were sold by Lippoldt Darin. $844,470 worth of stock was sold by Grigoriadis Dimitri E. on Wednesday, August 9. Gano Kyle also sold $276,420 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Wednesday, September 6.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 13. They expect $-0.03 EPS, up 94.12% or $0.48 from last year’s $-0.51 per share. After $-0.13 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -76.92% EPS growth.

Investors sentiment increased to 1.66 in 2017 Q3. Its up 0.41, from 1.25 in 2017Q2. It increased, as 22 investors sold Neurocrine Biosciences, Inc. shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Bb Biotech Ag has invested 5.87% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Victory Cap Mngmt has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 660 shares. Mirae Asset Glob Invests Limited holds 0.02% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 15,672 shares. Eventide Asset Lc owns 125,000 shares for 0.43% of their portfolio. Wells Fargo Company Mn invested in 945,368 shares or 0.02% of the stock. Shanda Asset Management Limited owns 10,000 shares for 0.08% of their portfolio. Pub Employees Retirement Association Of Colorado has 0.13% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Citigroup Inc has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Ubs Asset Mngmt Americas, a Illinois-based fund reported 519,712 shares. State Bank Of America Corp De holds 0.01% or 549,211 shares in its portfolio. Susquehanna Interest Gp Ltd Liability Partnership stated it has 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Dimensional Fund L P holds 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 181,751 shares. Jpmorgan Chase And has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Stifel Finance holds 4,029 shares. 252,593 were accumulated by Thrivent Financial For Lutherans.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $6.95 billion. The company??s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women??s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson??s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Investors sentiment decreased to 1.05 in Q3 2017. Its down 0.02, from 1.07 in 2017Q2. It turned negative, as 21 investors sold The Ultimate Software Group, Inc. shares while 104 reduced holdings. 52 funds opened positions while 79 raised stakes. 32.11 million shares or 2.37% less from 32.89 million shares in 2017Q2 were reported. Tocqueville Asset Mgmt L P invested in 4,125 shares or 0.01% of the stock. California Pub Employees Retirement Systems reported 78,352 shares. Evercore Wealth Mgmt Ltd Com holds 41 shares or 0% of its portfolio. Amalgamated Bancshares has 5,667 shares. Hrt Fincl Lc has invested 0.41% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Gemmer Asset Mgmt Ltd Liability has 0% invested in The Ultimate Software Group, Inc. (NASDAQ:ULTI) for 32 shares. Eulav Asset Management holds 115,800 shares. Summit Creek Limited Liability Corp holds 51,735 shares. Lombard Odier Asset Mngmt (Usa) Corporation owns 41,639 shares. First Mercantile Tru, a Tennessee-based fund reported 2,386 shares. Bokf Na reported 0.01% of its portfolio in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Westfield Capital Mngmt Lp holds 0.13% of its portfolio in The Ultimate Software Group, Inc. (NASDAQ:ULTI) for 86,605 shares. Dimensional Fund Advisors L P accumulated 0.01% or 77,546 shares. Tybourne Cap Management Hk Ltd holds 11.19% in The Ultimate Software Group, Inc. (NASDAQ:ULTI) or 770,173 shares. 11,982 are owned by Fincl Bank Of Montreal Can.

The stock increased 1.14% or $2.57 during the last trading session, reaching $228.83. About 369,891 shares traded or 20.07% up from the average. The Ultimate Software Group, Inc. (NASDAQ:ULTI) has risen 10.74% since January 18, 2017 and is uptrending. It has underperformed by 5.96% the S&P500.

The Ultimate Software Group, Inc. provides cloud human capital management solutions primarily to enterprise companies in the United States and Canada. The company has market cap of $6.84 billion. The companyÂ’s UltiPro software solution delivers the functionality businesses to manage the employee life cycle from recruitment to retirement. It has a 238.86 P/E ratio. The Company’s UltiPro solution includes unified feature sets for talent acquisition and onboarding, human resources management and compliance, benefits management and online enrollment, payroll, performance management, employee engagement surveying, compensation management with salary planning, budgeting, and development of incentive plans, succession management, learning management, reporting and analytical decision-making and predictive tools, and time and attendance; and has role features for HR professionals, executives, managers, administrators, and employees.

Since August 3, 2017, it had 0 buys, and 2 insider sales for $1.93 million activity. Manne Robert had sold 5,000 shares worth $1.00M. The insider FITZPATRICK JAMES A JR sold 4,613 shares worth $924,399.